Femicur has an inhibitory effect on prolactin release through a dopaminergic principle of action mediated by d2 receptors (binding inhibition). lowering the prolactin level cancels the disturbed secretion of gonadotrophins and normalizes the physiological estrogen/progesterone ratio which in turn abolishes the proliferative effect of prolactin on the mammary gland. additional action in relieving pre-menstrual syndrome may be mediated by opioid receptors binding inhibition.indications:-pre-menstrual syndrome.-mastalgia due to hormonal disturbances as hyper-prolactinemia.-menstrual disorders as menorrhagia, metrorrhagia, polymenorrhea and oligomenorrhea.dose: 1 caps in the morning for at least 3 monthes.